Evidence map›Paper›PMID 30123421›Full record

ArticleOncotarget2018

Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity.

Joel Uchuya-Castillo, Nicolas Aznar, Carla Frau, Pierre Martinez, Clementine Le Nevé, Laetitia Marisa, Luiz O F Penalva, Pierre Laurent-Puig, Alain Puisieux, Jean-Yves Scoazec and 3 more

Abstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Thyroid hormone signaling in the intestinal stem cells and their niche.Cellular and molecular life sciences : CMLS · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Joel Uchuya-CastilloCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.
Nicolas AznarCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.
Carla FrauCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.
Pierre MartinezCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.
Clementine Le NevéCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.
Laetitia MarisaProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris 75000, France.
Luiz O F PenalvaChildren's Cancer Research Institute, University of Texas Health Science Center at San Antonio, TX 78229, USA.
Pierre Laurent-PuigUMR-S 1147, Université Paris Descartes, Paris 75006, France.
Alain PuisieuxCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.
Jean-Yves ScoazecInstitute Gustave Roussy, Villejuif 94800, France.
Jacques SamarutInstitute de Génomique Fonctionnelle de Lyon, ENS de Lyon, Lyon 69342, France.
Stephane AnsieauCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.
Michelina PlaterotiCentre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard, Département de la recherche, Lyon 69000, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous work demonstrated a key function of the thyroid hormone nuclear receptor TRα1, a T3-modulated transcription factor, in controlling intestinal development and homeostasis

Indexed as

intestinal cancerthyroid hormonethyroid hormone nuclear receptorWnt antagonistWnt pathway

Identifiers

PMID30123421
PMCPMC6089551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.